Skip to main content
Retour
OPHLF logo

Ono Pharmaceutical Co., Ltd.

Qualité des données : 100%
OPHLF
OTC Healthcare Drug Manufacturers - General
14,00 €
0,00 € (0,00%)
Cap. Boursière : 6,58B
Également cotée sous OPHLY OTC
Fourchette du Jour
14,00 € 16,00 €
Fourchette 52 Semaines
9,20 € 18,67 €
Volume
625
Moyenne 50J / 200J
15,37 € / 12,48 €
Clôture Précédente
14,00 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 0,1 0,3
P/B 0,0 2,9
ROE % 6,4 3,7
Net Margin % 10,3 3,8
Rev Growth 5Y % 12,0 10,0
D/E 0,2 0,2

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 133,84 €
122,73 € – 144,81 €
470 B 1
FY2029 130,53 €
119,70 € – 141,24 €
470 B 1
FY2028 120,40 €
110,41 € – 130,27 €
450 B 1

Points Clés

Revenue grew 12,01% annually over 5 years — strong growth
Earnings declined -60,89% over the past year
Debt/Equity of 0,19 — conservative balance sheet
Generating 74,47B in free cash flow
P/E of 0,13 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 15,15%

Croissance

Revenue Growth (5Y)
12,01%
Revenue (1Y)-3,14%
Earnings (1Y)-60,89%
FCF Growth (3Y)-28,36%

Qualité

Return on Equity
6,35%
ROIC4,82%
Net Margin10,28%
Op. Margin12,27%

Sécurité

Debt / Equity
0,19
Current Ratio3,07
Interest Coverage11,23

Valorisation

P/E Ratio
0,13
P/B Ratio0,01
EV/EBITDA-0,86
Dividend Yield0,05%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -3,14% Revenue Growth (3Y) 4,34%
Earnings Growth (1Y) -60,89% Earnings Growth (3Y) -33,37%
Revenue Growth (5Y) 12,01% Earnings Growth (5Y) -9,75%
Profitability
Revenue (TTM) 486,87B Net Income (TTM) 50,05B
ROE 6,35% ROA 4,70%
Gross Margin 69,61% Operating Margin 12,27%
Net Margin 10,28% Free Cash Flow (TTM) 74,47B
ROIC 4,82% FCF Growth (3Y) -28,36%
Safety
Debt / Equity 0,19 Current Ratio 3,07
Interest Coverage 11,23 Dividend Yield 0,05%
Valuation
P/E Ratio 0,13 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio -0,26
EV/EBITDA -0,86 Dividend Yield 0,05%
Market Cap 6,58B Enterprise Value -51,31B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 486,87B 502,67B 447,19B 361,36B 309,28B
Net Income 50,05B 127,98B 112,72B 80,52B 75,43B
EPS (Diluted) 106,41 266,60 230,79 162,16 151,09
Gross Profit 338,92B 375,55B 337,13B 267,85B 223,71B
Operating Income 59,75B 163,10B 152,29B 114,91B 92,10B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,06T 913,67B 882,44B 739,20B 746,84B
Total Liabilities 275,84B 115,06B 134,62B 77,53B 105,69B
Shareholders' Equity 782,45B 792,96B 741,87B 655,91B 635,55B
Total Debt 146,68B 8,86B 9,17B 8,80B 9,05B
Cash & Equivalents 204,57B 166,14B 96,14B 69,11B 61,05B
Current Assets 455,10B 413,60B 345,10B 281,27B 247,64B
Current Liabilities 148,30B 103,62B 122,93B 65,93B 93,73B

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Defensive Investing (Benjamin Graham)
Mar 24, 2026